44.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Will Crinetics Pharmaceuticals Inc. benefit from macro trendsQuarterly Profit Review & Proven Capital Preservation Tips - newser.com
What recovery options are there for Crinetics Pharmaceuticals Inc.2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
Using data tools to time your Crinetics Pharmaceuticals Inc. exitJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
How to use a screener to detect Crinetics Pharmaceuticals Inc. breakouts2025 Technical Overview & Weekly Watchlist for Hot Stocks - newser.com
What candlestick patterns are forming on Crinetics Pharmaceuticals Inc.Buy Signal & Consistent Return Investment Signals - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
Crinetics Pharmaceuticals Inc. stock outlook for YEARJuly 2025 Breakouts & Weekly Setup with High ROI Potential - newser.com
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.July 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
Will Crinetics Pharmaceuticals Inc. stock keep outperforming rivalsWeekly Volume Report & High Yield Equity Trading Tips - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Is it too late to sell Crinetics Pharmaceuticals Inc.Market Trend Summary & Verified Swing Trading Watchlists - newser.com
Crinetics Pharmaceuticals' (CRNX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Will a bounce in Crinetics Pharmaceuticals Inc. offer an exit2025 Market Outlook & Fast Momentum Stock Entry Tips - newser.com
Crinetics stock holds Overweight rating at Piper Sandler after acromegaly drug approval - Investing.com Canada
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com Nigeria
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) - Yahoo Finance
A Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for Acromegaly - Yahoo Finance
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 15% Share Price Climb This Month - Sahm
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Using portfolio simulators with Crinetics Pharmaceuticals Inc. includedWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - newser.com
What MACD and RSI say about Crinetics Pharmaceuticals Inc.Earnings Recap Report & Capital Efficient Trade Techniques - newser.com
Does Crinetics Pharmaceuticals Inc. fit your quant trading model2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Comparing Crinetics Pharmaceuticals Inc. in custom built stock radarsMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized - Sahm
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Sells 5,000 Shares of Stock - MarketBeat
Crinetics Pharmaceuticals Hits Day High with 16.05% Surge in Stock Price - Markets Mojo
How analysts revise price targets for Crinetics Pharmaceuticals Inc. (6Z4) stockJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Crinetics Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Matthew Fust Sells 16,000 Shares - MarketBeat
Oppenheimer Raises Price Target on CRNX to $87, Maintains Outper - GuruFocus
Crinetics Pharmaceuticals (CRNX) Price Target Increased by 11.63% to 81.09 - Nasdaq
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval - MSN
Oppenheimer Raises Price Target on CRNX to $87, Maintains Outperform Rating | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Opens with 14.43% Gain, Surpassing S&P 500's 0.59% Rise - Markets Mojo
Crinetics Pharmaceuticals Inc 6Z4 Stock Analysis and ForecastQuarterly Earnings Review & Small Investment Capital Tips - earlytimes.in
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $87.00 at Oppenheimer - MarketBeat
Crinetics Pharmaceuticals Rings the Opening Bell - Nasdaq
What drives Crinetics Pharmaceuticals Inc stock priceFederal Reserve Announcements & Rapid Wealth Building Tips - earlytimes.in
JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating - MSN
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):